Skip to main content
Results of this study by Dr Fava show that most urinary BMs of histological activity were⬆️at 6 & 12mos in pts w

sheila

2 years 9 months ago
Results of this study by Dr Fava show that most urinary BMs of histological activity were⬆️at 6 & 12mos in pts who lost GFR at 3yrs. ☝️Some LN pts still develop renal damage despite clinical response. Is there a role for BMs in monitoring tx? #ACR23 ABST0850 @RheumNow #ACRbest https://t.co/H5G6LJ22lw
#ACR23 family memories! ⁦@KDAO2011⁩ ⁦@RheumNow⁩ https://t.co/SFa12nL4vR

Dr. Rachel Tate

2 years 9 months ago
#ACR23 family memories! ⁦@KDAO2011⁩ ⁦@RheumNow⁩ https://t.co/SFa12nL4vR
Taylor et al. Positive phase 2 RCT of Nipocalimab (neonatal Fc receptor blocking monoclonal) in RA. Abstr#0839 #ACR23 @R

Richard Conway

2 years 9 months ago
Taylor et al. Positive phase 2 RCT of Nipocalimab (neonatal Fc receptor blocking monoclonal) in RA. Abstr#0839 #ACR23 @RheumNow https://t.co/UHjti200yh https://t.co/tkSlLMIl7X
Ph2a Nipocalumab: FcRn blocker
IV15mg/kg TNF IR RA 32 pts
Delta DASCRP -1 vs -0.5 PBO
ACR50 20% vs 0 PBO
DAS Remission 4

Aurelie Najm

2 years 9 months ago
Ph2a Nipocalumab: FcRn blocker IV15mg/kg TNF IR RA 32 pts Delta DASCRP -1 vs -0.5 PBO ACR50 20% vs 0 PBO DAS Remission 40% vs 16% Only in ACPA+ pts SAEs 1 infusion related reaction Not extremely convincing alone Currently studied in combination w/ TNFi @RheumNow #ACR23 ABST0839 https://t.co/6wTu2ellhN
Utility of repeating assessments in chronic back pain pts suspected of early axSpA?
2 year study found a modest increase

Robert B Chao, MD

2 years 9 months ago
Utility of repeating assessments in chronic back pain pts suspected of early axSpA? 2 year study found a modest increase in new axSpA diagnosis after 2 years Yield of repeating MRI is low but can be considered in B27+ males @RheumNow #ACR23 Abs#0845 https://t.co/TgSEztUkTm
Few people are aware of the EULAR recommendations for cardiovascular risk management in SLE published in 2022.  The recommendations had 4 overarching principles: increase awareness of elevated cardiovascular risk, need for regular cardiovascular screening, assess and manage modifiable risk factors, and patient education. During ACR 2023 Convergence, several abstracts were presented evaluating the prevalence of CV disease and exploring new
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by R

Dr. John Cush RheumNow

2 years 9 months ago
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Ross et al. Fascinating study of infusion of etanercept into lymphatics in RA in inadequate responders to s/c etanercept

Richard Conway

2 years 9 months ago
Ross et al. Fascinating study of infusion of etanercept into lymphatics in RA in inadequate responders to s/c etanercept. DAS28(CRP) reduced 5.40±0.16 to 3.55±0.21, PGA of Disease Activity and Pain decreased by 66% and 77%. Abstr#0838 #ACR23 @RheumNow https://t.co/RIMCS3nmy6 https://t.co/U2689atvmj
LTE of REOVAS of RTX in EGPA. Relapse free survival 64% vs 51%, major relapse free 90% vs 79%. If MPO+ relapse free surv

Richard Conway

2 years 9 months ago
LTE of REOVAS of RTX in EGPA. Relapse free survival 64% vs 51%, major relapse free 90% vs 79%. If MPO+ relapse free survival 92% vs 50%. Abstr#0854 #ACR23 @RheumNow https://t.co/76hlYRxWhY https://t.co/RSsgxxQKVC
Dr. Jack Cush discusses abstract 0726 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Psoriatic arthritis and the gut microbiome have become more intertwined, especially in the past few years. It was to my amazement that one of the first abstracts I came across was the effect of probiotic modulation on gut dysbiosis and disease activity in psoriatic arthritis patients. 
Thank you @RheumNow I appreciate your mission and appreciate your team’s kindness today at #ACR23

#Lupus awareness i

Amanda G

2 years 9 months ago
Thank you @RheumNow I appreciate your mission and appreciate your team’s kindness today at #ACR23 #Lupus awareness is fun! https://t.co/ifRXxmpUaM
APIPPRA trial of abatacept to prevent RA in sero+ arthralgia. Picture paints a thousand words - big difference at week 5

Richard Conway

2 years 9 months ago
APIPPRA trial of abatacept to prevent RA in sero+ arthralgia. Picture paints a thousand words - big difference at week 52 (on abatacept) and watch those lines converge Abstr#0835 #ACR23 #ACRbest @RheumNow https://t.co/cwX389TUZN https://t.co/2CQHYlW0nq
IFN 5-gene signature to ID high IFN subsets as biomarkfor DEUC in PAISLEY P2 SLE trial
Ab847 #ACR23 @RheumNow
IFN 5 gene

Eric Dein

2 years 9 months ago
IFN 5-gene signature to ID high IFN subsets as biomarkfor DEUC in PAISLEY P2 SLE trial Ab847 #ACR23 @RheumNow IFN 5 gene score - 78% IFN-high pt IFN high ass w SLEDAI-2K, CLASI, PGA, dsDNA, low C3/C4/lmphocyte DEUC reduc IFN 5 gene score in both grps, best clin response in IFN hi https://t.co/WpZHE5z8za
×